{"id":52192,"date":"2023-09-20T09:30:03","date_gmt":"2023-09-20T09:30:03","guid":{"rendered":"https:\/\/medsname.com\/vesigard\/"},"modified":"2026-04-30T10:25:15","modified_gmt":"2026-04-30T10:25:15","slug":"vesigard","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/vesigard\/","title":{"rendered":"Vesigard"},"content":{"rendered":"

<\/p>\n

\n

R\u0103spuns rapid<\/h3>\n

Vesigard<\/strong> con\u021bine darifenacin eliberare prelungit\u0103 7,5 mg \/ 15 mg<\/strong> fabricat de Cipla Inc. Este utilizat pentru simptomele vezicii urinare hiperactive (VUH) \u2014 urgen\u021b\u0103 urinar\u0103, frecven\u021b\u0103 \u0219i incontinen\u021b\u0103 de urgen\u021b\u0103. Lua\u021bi exact conform indica\u021biilor medicului dumneavoastr\u0103 \u2014 nu ajusta\u021bi singur doza.<\/p>\n<\/div>\n

\nCe beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a>\n<\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n

\ud83d\udd12 Checkout criptat<\/strong> \u00b7 \ud83d\udcb3 Procesor verificat<\/strong> \u00b7 \ud83d\ude9a Livrare worldwide<\/strong> \u00b7 \u2b50 4,9\/5 de la peste 1.400 de clien\u021bi<\/strong><\/div>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

Fiecare lot este procurat de la un produc\u0103tor certificat WHO-GMP<\/strong>. Comenzile sunt expediate \u00een ambalaje simple, f\u0103r\u0103 marc\u0103, de la partenerii no\u0219tri de onorare \u0219i sunt acoperite de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>. Am servit 1.400+ clien\u021bi verifica\u021bi<\/strong> cu un rating mediu de 4,9\/5<\/strong> pe mai mult de 600 de medicamente.<\/p>\n

Ce este Vesigard \u0219i cum func\u021bioneaz\u0103<\/h2>\n

Vesigard con\u021bine darifenacin<\/strong>, un antagonist selectiv al receptorului M3 muscarinic<\/strong>. Detrusorul (mu\u0219chiul neted al vezicii urinare) se contract\u0103 \u00een principal prin receptorii M3; blocarea acestora reduce contrac\u021biile involuntare \u0219i urgen\u021ba \u0219i frecven\u021ba pe care le provoac\u0103. Selectivitatea pentru M3 a darifenacinei (~10\u00d7 mai mare dec\u00e2t pentru M1, M2) ofer\u0103 un profil de efecte adverse u\u0219or mai bun dec\u00e2t antimuscarinicele vechi neselective \u2014 risc mai mic de efecte adverse cognitive \u0219i tahicardie \u2014 dar gur\u0103 uscat\u0103 \u0219i constipa\u021bie apar \u00een continuare deoarece aceia\u0219i receptori M3 sunt prezen\u021bi \u00een glandele salivare \u0219i intestin.<\/p>\n

Vesigard este utilizat pentru complexul simptomatic de depozitare al OAB<\/strong>: urgen\u021b\u0103 (dorin\u021b\u0103 brusc\u0103 \u0219i imperioas\u0103 de a urina), frecven\u021b\u0103 (\u2265 8 mic\u021biuni la 24 de ore), nicturie \u0219i incontinen\u021b\u0103 de urgen\u021b\u0103. Nu este indicat pentru incontinen\u021ba de stres (sc\u0103p\u0103ri la tuse\/str\u0103nut), reten\u021bie urinar\u0103 sau obstruc\u021bie legat\u0103 de BPH.<\/p>\n

Doza \u0219i modul de administrare<\/h2>\n\n\n\n\n\n\n\n\n\n
Grup de pacien\u021bi<\/th>\nDoza recomandat\u0103<\/th>\n<\/tr>\n<\/thead>\n
Adul\u021bi cu OAB \u2014 doz\u0103 ini\u021bial\u0103<\/td>\n7,5 mg o dat\u0103 pe zi<\/strong><\/td>\n<\/tr>\n
Adul\u021bi \u2014 titrare dac\u0103 este necesar dup\u0103 2 s\u0103pt\u0103m\u00e2ni<\/td>\nCre\u0219te la 15 mg o dat\u0103 pe zi<\/strong><\/td>\n<\/tr>\n
Inhibitor puternic concomitent al CYP3A4 (ketoconazol, itraconazol, claritromicin\u0103, ritonavir, nefazodon\u0103)<\/td>\nLimita\u021bi la 7,5 mg\/zi; evita\u021bi 15 mg<\/td>\n<\/tr>\n
Insuficien\u021b\u0103 hepatic\u0103 moderat\u0103 (Child-Pugh B)<\/td>\nLimita\u021bi la 7,5 mg\/zi<\/td>\n<\/tr>\n
Afectare hepatic\u0103 sever\u0103 (Child-Pugh C)<\/td>\nEvita\u021bi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Lua\u021bi comprimatul \u00eentreg, cu sau f\u0103r\u0103 alimente, \u00een acela\u0219i moment al zilei.<\/strong> Nu zdrobi\u021bi, nu mesteca\u021bi \u0219i nu fr\u00e2nge\u021bi \u2014 matricea cu eliberare modificat\u0103 asigur\u0103 acoperire pe 24 de ore. \u00cembun\u0103t\u0103\u021birea simptomelor \u00eencepe \u00een 1-2 s\u0103pt\u0103m\u00e2ni; efectul complet \u00een 4-6 s\u0103pt\u0103m\u00e2ni. \u00centrerupe\u021bi \u0219i reevalua\u021bi dac\u0103 nu exist\u0103 beneficiu dup\u0103 8 s\u0103pt\u0103m\u00e2ni.<\/p>\n

\n

\u26a0 Sarcin\u0103 anticolinergic\u0103 \u2014 mai ales la adul\u021bii \u00een v\u00e2rst\u0103<\/strong><\/p>\n

Darifenacina contribuie la sarcina total\u0103 anticolinergic\u0103<\/strong> de la alte medicamente (TCA, antihistaminice sedative, oxibutinin\u0103, hioscin\u0103, anumite medicamente pentru Parkinson). O \u00eenc\u0103rc\u0103tur\u0103 anticolinergic\u0103 ridicat\u0103 pe parcursul lunilor a fost asociat\u0103 cu declin cognitiv \u0219i risc crescut de demen\u021b\u0103<\/strong> la adul\u021bii \u00een v\u00e2rst\u0103. Examina\u021bi medicamentele concomitente \u0219i utiliza\u021bi doza efectiv\u0103 cea mai mic\u0103. Mirabegronul (un agonist beta-3 f\u0103r\u0103 efect anticolinergic) este o alternativ\u0103 dac\u0103 \u00eenc\u0103rc\u0103tura este o problem\u0103.<\/p>\n<\/div>\n

Efecte secundare<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Efect secundar<\/th>\nFrecven\u021b\u0103<\/th>\nNote<\/th>\n<\/tr>\n<\/thead>\n
Gur\u0103 uscat\u0103<\/strong><\/td>\nFoarte frecvent (~20%)<\/td>\nGum\u0103 f\u0103r\u0103 zah\u0103r, hidratare, sorbit ap\u0103; de obicei se amelioraz\u0103<\/td>\n<\/tr>\n
Constipa\u021bie<\/strong><\/td>\nFoarte frecvent (~15%)<\/td>\nCre\u0219terea fibrelor \u0219i a lichidelor; laxativ cu volum dac\u0103 persist\u0103<\/td>\n<\/tr>\n
Ochi usca\u021bi<\/td>\nFrecvente<\/td>\nPic\u0103turi lubrifiante<\/td>\n<\/tr>\n
Indigestie\/grea\u021b\u0103<\/td>\nFrecvente<\/td>\nLua\u021bi cu m\u00e2ncare<\/td>\n<\/tr>\n
Vedere \u00eence\u021bo\u0219at\u0103<\/td>\nFrecvente<\/td>\nEvita\u021bi condusul p\u00e2n\u0103 v\u0103 obi\u0219nui\u021bi<\/td>\n<\/tr>\n
Reten\u021bie urinar\u0103<\/td>\nPu\u021bin frecvente<\/td>\n\u00centrerupe\u021bi \u0219i examina\u021bi \u2014 risc \u00een HBP<\/td>\n<\/tr>\n
Tahicardie<\/td>\nPu\u021bin frecvente<\/td>\nMai mic\u0103 dec\u00e2t agen\u021bii non-selectivi<\/td>\n<\/tr>\n
Efecte adverse cognitive (memorie, confuzie)<\/td>\nPu\u021bin frecvente<\/td>\nRisc mai mare la adul\u021bii \u00een v\u00e2rst\u0103<\/td>\n<\/tr>\n
Glaucom cu unghi \u00eenchis acut<\/td>\nRare<\/td>\nDurere ocular\u0103 \u2192 consult oftalmologic \u00een aceea\u0219i zi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Interac\u021biuni medicamentoase<\/h2>\n\n\n\n\n\n\n\n\n\n
Combina\u021bie<\/th>\nEfect<\/th>\nAc\u021biune<\/th>\n<\/tr>\n<\/thead>\n
Inhibitori puternici ai CYP3A4 (ketoconazol, itraconazol, ritonavir, claritromicin\u0103)<\/td>\nCre\u0219tere major\u0103 a nivelurilor de darifenacin\u0103<\/td>\nLimitare la 7,5 mg; evitare 15 mg<\/td>\n<\/tr>\n
Inductori puternici ai CYP3A4 (rifampicin\u0103, fenitoin\u0103, carbamazepin\u0103)<\/td>\nPierdere de efect<\/td>\nTrecere la o alternativ\u0103 non-CYP3A4<\/td>\n<\/tr>\n
Alte anticholinergice (oxibutinin\u0103, ATC, antihistaminice sedative, hioscin\u0103)<\/td>\nEfecte aditive: gur\u0103 uscat\u0103, constipa\u021bie, tulbur\u0103ri cognitive<\/td>\nReducere a \u00eenc\u0103rc\u0103turii acolo unde este posibil<\/td>\n<\/tr>\n
Substrate CYP2D6 cu fereastr\u0103 terapeutic\u0103 \u00eengust\u0103 (flecainid\u0103, imipramin\u0103)<\/td>\nNivelurile pot cre\u0219te prin inhibarea CYP2D6<\/td>\nMonitorizare \/ ajustare doz\u0103<\/td>\n<\/tr>\n
Digoxin\u0103<\/td>\nCre\u0219tere u\u0219oar\u0103 a nivelurilor de digoxin<\/td>\nMonitorizare de rutin\u0103<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Cine nu ar trebui s\u0103 ia Vesigard<\/h2>\n